Innoviva (INVA) Free Cash Flow (2010 - 2026)
Innoviva (INVA) reported Free Cash Flow of $34.8 million for Q1 2026, down 28.44% on a YoY basis from $48.6 million in Q1 2025, and down 75.38% quarter-over-quarter from $141.3 million in Q3 2025.
Innoviva (INVA) Free Cash Flow (2010 - 2026) Analysis & Trends
Innoviva has reported Free Cash Flow for 17 years, with the latest figure at $34.8 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 28.44% year-over-year to $34.8 million; the trailing twelve-month figure through Mar 2026 stood at $220.2 million (down 0.61% YoY), and the FY2025 full-year result was $195.8 million, up 3.92% from the prior year.
- Free Cash Flow for Q1 2026 stood at $34.8 million, down from $141.3 million in the prior quarter.
- The five-year high for Free Cash Flow was $192.8 million in Q3 2022, with the low at $25.7 million in Q1 2023.
- Historically, Free Cash Flow has averaged $78.5 million across 5 years, with a median of $48.6 million in 2025.
- Annual changes were most pronounced in 2023 — Free Cash Flow plunged 73.85% — and 2024, when it jumped 44.43%.
- Innoviva's Free Cash Flow stood at $192.8 million in 2022, then plunged by 44.22% to $107.5 million in 2023, then increased by 20.11% to $129.2 million in 2024, then gained by 9.38% to $141.3 million in 2025, then plunged by 75.38% to $34.8 million in 2026.
- The last three Free Cash Flow figures came in at $34.8 million (Q1 2026), $141.3 million (Q3 2025), and $44.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 63,220.27 |
| 10 | Innoviva | 1.69 Bn | 1.08 Bn | 75.83 Mn | 34.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.79 Mn |
| Mar 31, 2026 | 34.79 Mn |
| Sep 30, 2025 | 141.30 Mn |
| Sep 30, 2025 | 141.30 Mn |
| Jun 30, 2025 | 44.07 Mn |
| Jun 30, 2025 | 44.07 Mn |
| Mar 31, 2025 | 48.62 Mn |
| Mar 31, 2025 | 48.62 Mn |
| Sep 30, 2024 | 129.18 Mn |
| Sep 30, 2024 | 129.18 Mn |
| Jun 30, 2024 | 43.72 Mn |
| Jun 30, 2024 | 43.72 Mn |
| Mar 31, 2024 | 37.05 Mn |
| Mar 31, 2024 | 37.05 Mn |
| Sep 30, 2023 | 107.55 Mn |
| Sep 30, 2023 | 107.55 Mn |
| Jun 30, 2023 | 38.18 Mn |
| Jun 30, 2023 | 38.18 Mn |
| Mar 31, 2023 | 25.65 Mn |
| Mar 31, 2023 | 25.65 Mn |